Therapeutic effects of human mesenchymal and hematopoietic stem cells on rotenone-treated parkinsonian mice

Journal of Neuroscience Research

Volumn 91, Issue 1, 2013, Pages 62-72

  Inden, Masatoshi ^a   Takata, Kazuyuki ^a   Nishimura, Kaneyasu ^a   Kitamura, Yoshihisa ^a   Ashihara, Eishi ^a   Yoshimoto, Kanji ^b   Ariga, Hiroyoshi ^c   Honmou, Osamu ^d   Shimohama, Shun ^d  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone marrow; Cord blood; Parkinson's disease; Rotenone; Stem cells

Indexed keywords

ALPHA SYNUCLEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CD34 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; NERVE GROWTH FACTOR; ROTENONE; SOMATOMEDIN C; TYROSINE 3 MONOOXYGENASE;

ABNORMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CORPUS STRIATUM; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA PARS COMPACTA; THERAPY EFFECT;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, INBRED NOD; MICE, SCID; NERVE GROWTH FACTORS; PARKINSONIAN DISORDERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROTENONE; UNCOUPLING AGENTS;

EID: 84869148395     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23128     Document Type: Article

References (59)

1. Ali H, Bahbahani H. 2010. Umbilical cord blood stem cells-potential therapeutic tool for neural injuries and disorders. Acta Neurobiol Exp 70: 316-324.
2. Aponso PM, Faull RL, Connor B. 2010. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease. Neuroscience 151: 1142-1153.
3. Bassi EJ, de Almeida DC, Moraes-Vieira PM, Câmara NO. 2012. Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells. Stem Cell Rev 8: 329-342.
4. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306.
5. Borta A, Höglinger GU. 2007. Dopamine and adult neurogenesis. J Neurochem 100: 587-595.
6. Brazelton TR, Rossi FM, Keshet GI, Blau HM. 2000. From marrow to brain: expression of neuronal phenotypes in adult mice. Science 290: 1775-1779.
7. Chen Q, Long Y, Yuan X, Zou L, Sun J, Chen S, Perez-Polo JR, Yang K. 2005. Protective effects of bone marrow stromal cell transplantation in injured rodent brain: synthesis of neurotrophic factors. J Neurosci Res 80: 611-619.
8. Chen Y, Ai Y, Slevin JR, Maley BE, Gash DM. 2005. Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor. Exp Neurol 196: 87-95.
9. Cooper O, Isacson O. 2004. Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons. J Neurosci 24: 8924-8931.
10. Cummings BJ, Uchida N, Tamaki SJ, Salazar DL, Hooshmand M, Summers R, Gage FH, Anderson AJ. 2005. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc Natl Acad Sci U S A 102: 14069-14074.
11. Date I. 1996. Parkinson's disease, trophic factors, and adrenal medullary chromaffin cell grafting: basic and clinical studies. Brain Res Bull 40: 1-19.
12. Dezawa M, Kanno H, Hoshino M, Cho H, Matsumoto N, Itokazu Y, Tajima N, Yamada H, Sawada H, Ishikawa H, Mimura T, Kitada M, Suzuki Y, Ide C. 2004. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 113: 1701-1710.
13. Dunnett SB, Björklund A. 1999. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399(Suppl): A32-A39.
14. Fernandez-Espejo E. 2004. Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. Mol Neurobiol 29: 15-30.
15. Fierro FA, Kalomoiris S, Sondergaard CS, Nolta JA. 2011. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy. Stem Cells 29: 1727-1737.
16. Freed CR. 2002. Will embryonic stem cells be a useful source of dopamine neurons for transplantation into patients with Parkinson's disease. Proc Natl Acad Sci U S A 99: 1755-1757.
17. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344: 710-719.
18. Frielingsdorf H, Schwarz K, Brundin P, Mohapel P. 2004. No evidence for new dopaminergic neurons in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A 101: 10177-10182.
19. Goldman S. 2005. Stem and progenitor cell-based therapy of the human central nervous system. Nat Biotechnol 23: 862-871.
20. - cells in cord blood and bone marrow. Blood 86: 3745-3753.
21. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, Lin LF, Gerhardt GA. 1994. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182: 107-111.
22. Hokari M, Kuroda S, Shichinohe H, Yano S, Hida K, Iwasaki Y. 2008. Bone marrow stromal cells protect and repair damaged neurons through multiple mechanisms. J Neurosci Res 86: 1024-1035.
23. Hokari M, Kuroda S, Chiba Y, Maruichi K, Iwasaki Y. 2009. Synergistic effects of granulocyte-colony stimulating factor on bone marrow stromal cell transplantation for mice cerebral infarct. Cytokine 46: 260-266.
24. Huot P, Lévesque M, Parent A. 2007. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 130: 222-232.
25. Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, Taira T, Ariga H, Shimohama S. 2007. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 101: 1491-1504.
26. Inden M, Kitamura Y, Abe M, Tamaki A, Takata K, Taniguchi T. 2011. Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol Pharm Bull 34: 92-96.
27. Kay JN, Blum M. 2000. Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection. Dev Neurosci 22: 56-67.
28. 2-receptor subfamily agonists. Neurochem Res 28: 1035-1040.
29. Kitamura Y, Inden M, Minamino H, Abe M, Takata K, Taniguchi T. 2010. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra. Glia 58: 1686-1700.
30. Kordower JH. 2003. In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann Neurol 53(Suppl 3): S120-S132.
31. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD. 1999. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46: 419-424.
32. Lange AE, Lozano AM. 1998. Parkinson's disease: second of two parts. N Engl J Med 339: 1130-1143.
33. Li Y, Chen J, Wang L, Zhang L, Lu M, Chopp M. 2001. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett 316: 67-70.
34. Lie DC, Dziewczapolski G, Willhoite AR, Kaspar BK, Shults CW, Gage FH. 2002. The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci 22: 6639-6649.
35. Lu P, Blesch A, Tuszynski MH. 2004. Induction of bone marrow stromal cells to neurons: differentiation, transdifferentiation, or artifact? J Neurosci Res 77: 174-191.
36. Mao L, Lau YS, Petroske E, Wang JQ. 2001. Profound astrogenesis in the striatum of adult mice following nigrostriatal dopaminergic lesion by repeated MPTP administration. Brain Res Dev Brain Res 131: 57-65.
37. Martins AA, Paiva A, Morgado JM, Gomes A, Pais ML. 2009. Quantification and immunophenotypic characterization of bone marrow and umbilical cord blood mesenchymal stem cells by multicolor flow cytometry. Transplant Proc 41: 943-946.
38. Mendez I, Viñuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O. 2008. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 14: 507-509.
39. Mohapel P, Frielingsdorf H, Häggblad J, Zachrisson O, Brundin P. 2005. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions. Neuroscience 132: 767-776.
40. Olanow CW, Koller WC. 1998. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 50(Suppl 3): S1-S57.
41. Park HJ, Lee PH, Bang OY, Lee G, Ahn YH. 2008. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J Neurochem 107: 141-151.
42. Pawitan JA. 2011. Prospect of cell therapy for Parkinson's disease. Anat Cell Biol 44: 256-264.
43. Peterson AL, Nutt JG. 2008. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5: 270-280.
44. Politis M, Lindvall O. 2012. Clinical application of stem cell therapy in Parkinson's disease. BMC Med 10: 1.
45. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
46. Reimers D, Herranz AS, Díaz-Gil JJ, Lobo MV, Paíno CL, Alonso R, Asensio MJ, Gonzalo-Gobernado R, Bazán E. 2006. Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats. J Histochem Cytochem 54: 457-465.
47. Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, Ilan AB, Bulvik S, Shemesh N, Krepel D, Cohen Y, Melamed E, Offen D. 2009. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev 18: 1179-1190.
48. Shan X, Chi L, Bishop M, Luo C, Lien L, Zhang Z, Liu R. 2006. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson's disease-like mice. Stem Cells 24: 1280-1287.
49. Shen LH, Li Y, Chen J, Zacharek A, Gao Q, Kapke A, Lu M, Raginski K, Vanguri P, Smith A, Chopp M. 2007. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab 27: 6-13.
50. Shimohama S, Sawada H, Kitamura Y, Taniguchi T. 2003. Disease model: Parkinson's disease. Trends Mol Med 9: 360-365.
51. Shintani A, Nakao N, Kakishita K, Itakura T. 2007. Protection of dopamine neurons by bone marrow stromal cells. Brain Res 1186: 48-55.
52. +) implantation induces neuroplasticity by enhancing beta1 integrin-mediated angiogenesis in chronic stroke rats. J Neurosci 26: 3444-3453.
53. +) implanted-Parkinson's model. J Neurosci Res 87: 2020-2033.
54. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302: 841.
55. Steiner B, Winter C, Hosman K, Siebert E, Kempermann G, Petrus DS, Kupsch A. 2006. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease. Exp Neurol 199: 291-300.
56. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL. 2000. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 97: 14720-14725.
57. Wang F, Yasuhara T, Shingo T, Kameda M, Tajiri N, Yuan WJ, Kondo A, Kadota T, Baba T, Tayra JT, Kikuchi Y, Miyoshi Y, Date I. 2010. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci 11: 52.
58. Zhao M, Momma S, Delfani K, Carlen M, Cassidy RM, Johansson CB, Brismar H, Shupliakov O, Frisen J, Janson AM. 2003. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A 100: 7925-7930.
59. Zheng W, Honmou O, Miyata K, Harada K, Suzuki J, Liu H, Houkin K, Hamada H, Kocsis JD. 2010. Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. Brain Res 1310: 8-16.